Blood Advances - Belumosudil BOS (clinical study)

Clinical study on the efficacy of belumosudil (ROCK2 inhibitor) in post-stem cell transplant BOS. Promising results approved by the FDA.

https://pubmed.ncbi.nlm.nih.gov/36083121/